Dr Reddy's Labs

{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,201.30",
    "chg": -21.2,
    "chgp": "-1.73%",
    "dir": -1,
    "prev_price": "1,222.50",
    "mcapval": "100,264.14 Cr",
    "mcap": "Large Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE089A01031",
    "curr_date": "Jan 29",
    "curr_time": "",
    "bse_nse_vol": "8.02 lacs",
    "exc_status": "Active",
    "traded_date": "Jan 29, 2026",
    "traded_date_str": "2026 01 29",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-reddy-s-labs-734514-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Dr Reddys Laboratories Ltd Faces Sell Downgrade Amid Nifty 50 Membership Significance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-sell-downgrade-amid-nifty-50-membership-significance-3808937",
        "imagepath": "",
        "date": "2026-01-29 09:20:58",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>As a key component of the Nifty 50 index, Dr Reddys Laboratories Ltd holds a critical position in India’s equity market landscape. Inclusion in this benchmark index not only enhances the stock’s visibility among domestic and international investors but also ensures substantial liquidity and institutional interest. The company’s market capitalisation stands at a robust ₹1,00,581.30 crores, categorising it firmly as a large-cap stock. This stature typically attracts passive funds tracking the Nifty 50, thereby providing a degree of price support and stability.</p>\n                <p>However, the recent performance metrics indicate that Dr Reddys is struggling to maintain its momentum. The stock has declined by 1..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Institutional Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-institutional-shifts-3806945",
        "imagepath": "",
        "date": "2026-01-28 09:21:01",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Index Membership: A Double-Edged Sword</strong></p>\n                <p>Being part of the Nifty 50 index confers Dr Reddys Laboratories Ltd a prestigious status, reflecting its market capitalisation, liquidity, and sector representation. With a market cap of ₹1,03,602.67 crores, it firmly sits among India’s large-cap elite. This membership ensures substantial passive fund inflows, as index-tracking funds and ETFs allocate capital in line with the index composition. However, it also subjects the stock to heightened scrutiny and volatility linked to broader index movements.</p>\n                <p>Dr Reddys’ current valuation metrics reveal a price-to-earnings (P/E) ratio of 18.59, notably below the Pharmaceuticals & Biotechnology sector average of 32.47. This discount suggests th..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Institutional Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-institutional-shifts-3805066",
        "imagepath": "",
        "date": "2026-01-27 09:20:57",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>As a constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a critical position within India’s premier equity benchmark. Inclusion in this index not only reflects the company’s market capitalisation and liquidity but also ensures substantial institutional interest, particularly from index funds and passive investors. The stock’s market cap currently stands at a robust ₹1,04,036.67 crores, categorising it firmly as a large-cap entity within the Pharmaceuticals & Biotechnology sector.</p>\n                <p>Being part of the Nifty 50 means Dr Reddys is often a bellwether for sectoral and broader market trends. Its performance can influence the sectoral index and, by extension, the overall market sentiment..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-ltd-is-rated-sell-3804146",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/DrReddysLaborat_mojoScore_3804146.png",
        "date": "2026-01-25 10:10:04",
        "description": "Dr Reddys Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 January 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Dr Reddys Laboratories Gains 5.07%: 4 Key Factors Driving the Weekly Move",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-gains-507-4-key-factors-driving-the-weekly-move-3803505",
        "imagepath": "",
        "date": "2026-01-24 16:00:08",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Jan 19:</strong> Death Cross formation signals bearish trend</p>\n                    <p><strong>Jan 20:</strong> Bearish momentum intensifies amid technical downturn</p>\n                    <p><strong>Jan 21:</strong> Q3 FY26 results reveal margin pressures despite revenue resilience</p>\n                    <p><strong>Jan 22:</strong> Intraday high surge of 4.98% with strong gap up opening</p>\n                    <p><strong>Jan 23:</strong> Week closes at Rs.1,235.15 (+1.48%) outperforming Sensex</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,175.55</..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Mixed Performance and Institutional Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-performance-and-institutional-shifts-3801113",
        "imagepath": "",
        "date": "2026-01-23 09:21:09",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being part of the Nifty 50 index confers considerable advantages to Dr Reddys Laboratories Ltd, including enhanced visibility among domestic and global investors, increased liquidity, and inclusion in numerous index-tracking funds and ETFs. This membership not only bolsters the company’s profile but also influences trading volumes and price stability. However, it also subjects the stock to heightened scrutiny and performance expectations relative to peers within the Pharmaceuticals & Biotechnology sector and the broader market.</p>\n\n                <p><strong>Recent Market Performance and Valuation</strong></p>\n                <p>Dr Reddys Laboratories Ltd currently holds a market capitalisation of ₹1,01,587 c..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Hits Intraday High with 4.98% Surge on 22 Jan 2026",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-hits-intraday-high-with-498-surge-on-22-jan-2026-3799653",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/DrReddysLaborat_priceRelatedfactors_3799653.png",
        "date": "2026-01-22 09:31:32",
        "description": "Dr Reddys Laboratories Ltd demonstrated robust intraday performance on 22 Jan 2026, surging to a day’s high of Rs 1211.5, marking a 4.85% increase from the previous close. The stock outperformed its sector and the broader market, reflecting heightened trading activity and volatility."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Opens Strong with Significant Gap Up Amid Positive Market Sentiment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-opens-strong-with-significant-gap-up-amid-positive-market-sentiment-3799639",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/DrReddysLaborat_gapup_3799639.png",
        "date": "2026-01-22 09:30:32",
        "description": "Dr Reddys Laboratories Ltd commenced trading on 22 Jan 2026 with a notable gap up, opening 3.13% higher than the previous close, reflecting a strong start and positive market sentiment in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Mixed Performance and Institutional Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-performance-and-institutional-shifts-3799390",
        "imagepath": "",
        "date": "2026-01-22 09:20:52",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being part of the Nifty 50 index confers considerable advantages to Dr Reddys Laboratories Ltd, including enhanced visibility among domestic and global investors, increased liquidity, and automatic inclusion in numerous index-tracking funds and ETFs. This benchmark status often acts as a stabilising factor during volatile market phases, as institutional investors and mutual funds maintain or adjust their holdings in line with index rebalancing requirements.</p>\n                <p>Dr Reddys’ market capitalisation currently stands at a robust ₹1,00,589.65 crores, cementing its position as a large-cap entity within the Pharmaceuticals & Biotechnology sector. The company’s price-to-earnings (P/E) ratio of 16.71 is..."
      }
    ],
    "total": 455,
    "sid": "734514",
    "stock_news_url": "https://www.marketsmojo.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "details": "Dr. Reddy's Laboratories Limited has submitted to the Exchange a copy of Disclosure of Related Party Transactions for the period ended September 30, 2019.",
      "source": "NSE",
      "caption": "Dr. Reddy's Laboratories Limited - Other General Purpose",
      "datetime": "28-Nov-2019"
    },
    {
      "details": "Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated November 22, 2019, titled \"Dr. Reddy's Laboratories announces launch of",
      "source": "NSE",
      "caption": "Dr. Reddy's Laboratories Limited - Press Release",
      "datetime": "22-Nov-2019"
    },
    {
      "details": "Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated November 14, 2019, titled \"Dr. Reddy s Laboratories enters Nutrition Segment with Celevida in India.\".",
      "source": "NSE",
      "caption": "Dr. Reddy's Laboratories Limited - Press Release",
      "datetime": "14-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 25",
          "dt": "2025-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Dr Reddys Laboratories Ltd Faces Sell Downgrade Amid Nifty 50 Membership Significance

2026-01-29 09:20:58

Significance of Nifty 50 Membership

As a key component of the Nifty 50 index, Dr Reddys Laboratories Ltd holds a critical position in India’s equity market landscape. Inclusion in this benchmark index not only enhances the stock’s visibility among domestic and international investors but also ensures substantial liquidity and institutional interest. The company’s market capitalisation stands at a robust ₹1,00,581.30 crores, categorising it firmly as a large-cap stock. This stature typically attracts passive funds tracking the Nifty 50, thereby providing a degree of price support and stability.

However, the recent performance metrics indicate that Dr Reddys is struggling to maintain its momentum. The stock has declined by 1...

Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Institutional Shifts

2026-01-28 09:21:01

Index Membership: A Double-Edged Sword

Being part of the Nifty 50 index confers Dr Reddys Laboratories Ltd a prestigious status, reflecting its market capitalisation, liquidity, and sector representation. With a market cap of ₹1,03,602.67 crores, it firmly sits among India’s large-cap elite. This membership ensures substantial passive fund inflows, as index-tracking funds and ETFs allocate capital in line with the index composition. However, it also subjects the stock to heightened scrutiny and volatility linked to broader index movements.

Dr Reddys’ current valuation metrics reveal a price-to-earnings (P/E) ratio of 18.59, notably below the Pharmaceuticals & Biotechnology sector average of 32.47. This discount suggests th...

Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Institutional Shifts

2026-01-27 09:20:57

Significance of Nifty 50 Membership

As a constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a critical position within India’s premier equity benchmark. Inclusion in this index not only reflects the company’s market capitalisation and liquidity but also ensures substantial institutional interest, particularly from index funds and passive investors. The stock’s market cap currently stands at a robust ₹1,04,036.67 crores, categorising it firmly as a large-cap entity within the Pharmaceuticals & Biotechnology sector.

Being part of the Nifty 50 means Dr Reddys is often a bellwether for sectoral and broader market trends. Its performance can influence the sectoral index and, by extension, the overall market sentiment...

Read full news article

Dr Reddys Laboratories Ltd is Rated Sell

2026-01-25 10:10:04

Dr Reddys Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Dr Reddys Laboratories Gains 5.07%: 4 Key Factors Driving the Weekly Move

2026-01-24 16:00:08

Key Events This Week

Jan 19: Death Cross formation signals bearish trend

Jan 20: Bearish momentum intensifies amid technical downturn

Jan 21: Q3 FY26 results reveal margin pressures despite revenue resilience

Jan 22: Intraday high surge of 4.98% with strong gap up opening

Jan 23: Week closes at Rs.1,235.15 (+1.48%) outperforming Sensex

Week Open

Rs.1,175.55Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Mixed Performance and Institutional Shifts

2026-01-23 09:21:09

Significance of Nifty 50 Membership

Being part of the Nifty 50 index confers considerable advantages to Dr Reddys Laboratories Ltd, including enhanced visibility among domestic and global investors, increased liquidity, and inclusion in numerous index-tracking funds and ETFs. This membership not only bolsters the company’s profile but also influences trading volumes and price stability. However, it also subjects the stock to heightened scrutiny and performance expectations relative to peers within the Pharmaceuticals & Biotechnology sector and the broader market.

Recent Market Performance and Valuation

Dr Reddys Laboratories Ltd currently holds a market capitalisation of ₹1,01,587 c...

Read full news article

Dr Reddys Laboratories Ltd Hits Intraday High with 4.98% Surge on 22 Jan 2026

2026-01-22 09:31:32

Dr Reddys Laboratories Ltd demonstrated robust intraday performance on 22 Jan 2026, surging to a day’s high of Rs 1211.5, marking a 4.85% increase from the previous close. The stock outperformed its sector and the broader market, reflecting heightened trading activity and volatility.

Read full news article

Dr Reddys Laboratories Ltd Opens Strong with Significant Gap Up Amid Positive Market Sentiment

2026-01-22 09:30:32

Dr Reddys Laboratories Ltd commenced trading on 22 Jan 2026 with a notable gap up, opening 3.13% higher than the previous close, reflecting a strong start and positive market sentiment in the Pharmaceuticals & Biotechnology sector.

Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Mixed Performance and Institutional Shifts

2026-01-22 09:20:52

Significance of Nifty 50 Membership

Being part of the Nifty 50 index confers considerable advantages to Dr Reddys Laboratories Ltd, including enhanced visibility among domestic and global investors, increased liquidity, and automatic inclusion in numerous index-tracking funds and ETFs. This benchmark status often acts as a stabilising factor during volatile market phases, as institutional investors and mutual funds maintain or adjust their holdings in line with index rebalancing requirements.

Dr Reddys’ market capitalisation currently stands at a robust ₹1,00,589.65 crores, cementing its position as a large-cap entity within the Pharmaceuticals & Biotechnology sector. The company’s price-to-earnings (P/E) ratio of 16.71 is...

Read full news article

View All News